List of works by Owen A. O'Connor

<i>N</i>-quinoline-benzenesulfonamide derivatives exert potent anti-lymphoma effect by targeting NF-κB

scientific article published on 30 November 2020

A Case of Bing-Neel Syndrome Successfully Treated with Ibrutinib

scientific article published on 28 August 2018

A Phase 1 Study of TTI-621, a Novel Immune Checkpoint Inhibitor Targeting CD47, in Patients with Relapsed or Refractory Hematologic Malignancies ⬇️

scholarly article

A Phase 1 Study of the Anti-CD37 Antibody-Drug Conjugate AGS67E in Advanced Lymphoid Malignancies. Interim Results ⬇️

scholarly article

A Phase I Study of ADCT-402 (Loncastuximab Tesirine), a Novel Pyrrolobenzodiazepine-Based Antibody-Drug Conjugate, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma

scientific article published on 04 November 2019

A Phase I/II Trial of the Kinesin Spindle Protein (KSP) Inhibitor SB-743921 Dosed Q14D without and with Prophylactic G-CSF in Non-Hodgkin (NHL) or Hodgkin Lymphoma (HL). ⬇️

scholarly article

A critical analysis of prognostic factors in North American patients with human T-cell lymphotropic virus type-1-associated adult T-cell leukemia/lymphoma: a multicenter clinicopathologic experience and new prognostic score

scientific article published in July 2010

A multi-institutional experience of autologous stem cell transplantation in North American patients with human T-cell lymphotropic virus type-1 adult T-cell leukemia/lymphoma suggests ineffective salvage of relapsed patients

scientific article published in June 2009

A multicentre phase II clinical experience with the novel aza-epothilone Ixabepilone (BMS247550) in patients with relapsed or refractory indolent non-Hodgkin lymphoma and mantle cell lymphoma

scientific article published on 4 August 2008

A peripheral T-cell lymphoma (PTCL) arising as a post-transplant lymphoproliferative disorder: efficacy of pralatrexate in primary refractory disease and review of the literature

scientific article published on 11 June 2019

A perspective on improving the R-CHOP regimen: from Mega-CHOP to ROBUST R-CHOP, the PHOENIX is yet to rise

scientific article published on 01 November 2020

A phase 1 dose escalation study of the safety and pharmacokinetics of the novel proteasome inhibitor carfilzomib (PR-171) in patients with hematologic malignancies

scientific article

A phase 1 study of romidepsin and pralatrexate reveals marked activity in relapsed and refractory T-cell lymphoma.

scientific article

A phase 1/2 trial of ublituximab, a novel anti-CD20 monoclonal antibody, in patients with B-cell non-Hodgkin lymphoma or chronic lymphocytic leukaemia previously exposed to rituximab

scientific article

A phase I single-agent study of twice-weekly consecutive-day dosing of the proteasome inhibitor carfilzomib in patients with relapsed or refractory multiple myeloma or lymphoma

scientific article

ATM inhibition overcomes resistance to histone deacetylase inhibitor due to p21 induction and cell cycle arrest

scientific article published on 15 September 2020

Abstract CT132: Umbralisib monotherapy demonstrates efficacy and safety in patients with relapsed/refractory marginal zone lymphoma: A multicenter, open-label, registration directed Phase II study

scholarly article

Activity of a novel anti-folate (PDX, 10-propargyl 10-deazaaminopterin) against human lymphoma is superior to methotrexate and correlates with tumor RFC-1 gene expression.

scientific article

Acute orbitocranial inflammation following radioimmunotherapy for non-Hodgkin lymphoma

scientific article published on 01 May 2010

Adverse prognostic significance of CD20 positive Reed-Sternberg cells in classical Hodgkin's disease*

scientific article published on 01 June 2004

Angioimmunoblastic T-cell lymphoma with an evolving Epstein Barr virus-positive diffuse large B-cell lymphoma with unusual clinical and pathologic findings.

scientific article

At long last, it's finally 'T' time

scientific article

Aurora A Kinase Inhibition Selectively Synergizes with Histone Deacetylase Inhibitor through Cytokinesis Failure in T-cell Lymphoma.

scientific article

Belinostat Induces High Overall Response Rate (ORR) in Patients with Relapsed or Refractory Angioimmunoblastic T-Cell Lymphoma (AITL) ⬇️

scholarly article

Belinostat in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma: Results of the Pivotal Phase II BELIEF (CLN-19) Study.

scientific article

Belinostat in patients with refractory or relapsed peripheral T-cell lymphoma: a perspective review

scientific article

Bone marrow involvement in patients with posttransplant lymphoproliferative disorders: incidence and prognostic factors

scientific article published on 8 April 2010

Bortezomib In Combination with Rituximab, Cyclophosphamide, and Prednisone with or without Doxorubicin Followed by Rituximab Maintenance In Patients with Relapsed or Refractory Follicular Lymphoma: Results of a Phase 2 Study. ⬇️

scholarly article

Bortezomib disrupts tumour-dendritic cell interactions in myeloma and lymphoma: therapeutic implications

scientific article published on January 2007

Bortezomib-induced tumor lysis syndrome in a patient with HIV-negative plasmablastic lymphoma

scientific article published on October 2010

Brentuximab vedotin activity in diffuse large B-cell lymphoma with CD30 undetectable by visual assessment of conventional immunohistochemistry

scientific article

Brentuximab vedotin and bendamustine produce high complete response rates in patients with chemotherapy refractory Hodgkin lymphoma.

scientific article published on 16 December 2016

Brentuximab vedotin plus bendamustine in relapsed or refractory Hodgkin's lymphoma: an international, multicentre, single-arm, phase 1-2 trial

scientific article published on 21 December 2017

Brentuximab vedotin plus bendamustine: a highly active first salvage regimen for relapsed or refractory Hodgkin lymphoma.

scientific article published on 27 April 2018

Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial

scientific article published on 04 December 2018

Brentuximab vedotin, an antibody-drug conjugate, in patients with CD30-positive haematologic malignancies and hepatic or renal impairment.

scientific article published on 26 April 2016

CYP3A-mediated drug-drug interaction potential and excretion of brentuximab vedotin, an antibody-drug conjugate, in patients with CD30-positive hematologic malignancies

scientific article published on 10 June 2013

Cancer Testis Antigen Expression Across T-Cell Lymphoma Subtypes

scientific article published on 03 August 2020

Case Match Control Analysis of Propel Reveals Survival Advantage for Patients with Relapsed/Refractory (R/R) Peripheral T-Cell Lymphoma (PTCL) Treated with Pralatrexate ⬇️

scholarly article

Casein Kinase 1 Delta Is a Novel Regulator of mRNA Translation and Druggable Target in Aggressive Lymphomas ⬇️

scholarly article

Changing the paradigms of treatment in peripheral T-cell lymphoma: from biology to clinical practice.

scientific article published in October 2014

Characterization of newly established Pralatrexate-resistant cell lines and the mechanisms of resistance

scientific article published on 31 July 2021

Characterizing the belinostat response in patients with relapsed or refractory angioimmunoblastic T-cell lymphoma

scientific article published on 26 April 2020

Clinical and Biological Evaluation of the Novel CD30/CD16A Tetravalent Bispecific Antibody (AFM13) in Relapsed or Refractory CD30-Positive Lymphoma with Cutaneous Presentation: A Biomarker Phase Ib/IIa Study (NCT03192202) ⬇️

scholarly article

Clinical experience with intravenous and oral formulations of the novel histone deacetylase inhibitor suberoylanilide hydroxamic acid in patients with advanced hematologic malignancies

scientific article

Combination anti-CD74 (milatuzumab) and anti-CD20 (rituximab) monoclonal antibody therapy has in vitro and in vivo activity in mantle cell lymphoma

scientific article

Combination of Epigenetic Agents Synergistically Reverse the Malignant Phenotype in Models of T-Cell Lymphoma ⬇️

scholarly article

Combination of ibrutinib and chemotherapy produced a durable remission in multiply relapsed diffuse large B-cell lymphoma leg type with mutant MYD88 and wildtype CD79.

scientific article published on 24 March 2017

Combined Hypomethylating Agents (HMA) and Histone Deacetylase Inhibitors (HDACi) Exhibit Compelling Activity in Patients with Peripheral T-Cell Lymphoma (PTCL) with High Complete Response Rates in Angioimmunoblastic T-Cell Lymphoma (AITL) ⬇️

scholarly article

Combined Oral 5-Azacytidine and Romidepsin are Highly Effective in Patients with PTCL: A Multicenter Phase 2 Study

scientific article published on 10 November 2020

Comparative animal models for the study of lymphohematopoietic tumors: strengths and limitations of present approaches

scientific article

Complementary Targeting of PI3K and the Proteasome Causes Potent Inhibition of mTORC1 and NF-Kappab in Models of B- and T-Cell Lymphoma ⬇️

scholarly article

Concurrent and apposed hepatocellular carcinoma and small lymphocytic lymphoma/chronic lymphocytic leukemia in a patient with hepatitis C virus.

scientific article

Developing new drugs for the treatment of lymphoma

scientific article

Development and Characterization of Two Lymphoma Cell Lines Resistant to the Selective HDAC6 Inhibitor Ricolinostat (ACY-1215) As a Tool to Better Understand the Biology of HDACs on Lymphoma ⬇️

scholarly article

Development and characterization of a Mantle Cell Lymphoma Cell Bank in the American Type Culture Collection

2015 scientific article

Development and characterization of a novel CD19CherryLuciferase (CD19CL) transgenic mouse for the preclinical study of B-cell lymphomas

scientific article

Diagnostic accuracy of computed tomography using lower doses of radiation for patients with Crohn's disease.

scientific article

Diffuse aggressive lymphoma

scientific article

Disruption of the mTOR-eIF4F Axis By Selectively Targeting PI3Kdelta and Proteasome Potently Inhibits Cap Dependent Translation of c-Myc in Aggressive Lymphomas ⬇️

scholarly article

Drug-induced cutaneous vasculitis in patients with non-Hodgkin lymphoma treated with the novel proteasome inhibitor bortezomib: a possible surrogate marker of response?

scientific article published on 01 August 2006

Dual Targeting With The Selective Histone Deacetylase (HDAC) 6 Inhibitor, ACY-1215, and Bortezomib (BOR) Leads To Marked Disruption Of Protein Degradation Pathways and Apoptosis In Preclinical Models Of Lymphoma ⬇️

scholarly article

Dual Targeting of Protein Degradation Pathways with the Selective HDAC6 Inhibitor ACY-1215 and Bortezomib Is Synergistic in Lymphoma

scientific article

Emerging role of carfilzomib in treatment of relapsed and refractory lymphoid neoplasms and multiple myeloma.

scientific article

Emerging role of epigenetic therapies in cutaneous T-cell  lymphomas.

scientific article published on April 2010

Emerging therapies in relapsed and refractory peripheral T-cell lymphoma

scientific article published on December 2015

Epigenetic Targeting with EZH2 and HDAC Inhibitors Is Synergistic in EZH2 Deregulated Lymphomas ⬇️

scholarly article

Epigenetics and Lymphoma: Can We Use Epigenetics to Prime or Reset Chemoresistant Lymphoma Programs?

scientific article published on September 2015

Erratum to "A Case of Bing-Neel Syndrome Successfully Treated with Ibrutinib"

scientific article published on 29 October 2018

Everolimus for patients with mantle cell lymphoma refractory to or intolerant of bortezomib: multicentre, single-arm, phase 2 study

scientific article

Extended treatment with brentuximab vedotin in patients with relapsed or refractory CD30-positive hematological malignancies

scientific article published on 07 October 2014

FDG-PET lymphoma demonstration project invitational workshop

scientific article published on 01 March 2007

Fbxw7α- and GSK3-mediated degradation of p100 is a pro-survival mechanism in multiple myeloma

scientific article published on 4 March 2012

Final Results of a Phase 1 Study of Loncastuximab Tesirine in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma

scientific article published on 19 November 2020

For disease in need, a Friend indeed

scientific article published on 01 June 2011

Generation of pralatrexate resistant T-cell lymphoma lines reveals two patterns of acquired drug resistance that is overcome with epigenetic modifiers

scientific article published on 02 July 2020

HDAC inhibitors and decitabine are highly synergistic and associated with unique gene-expression and epigenetic profiles in models of DLBCL

scientific article published on 19 July 2011

High rate of complete responses to immune checkpoint inhibitors in patients with relapsed or refractory Hodgkin lymphoma previously exposed to epigenetic therapy

scientific article published on 30 November 2016

High-dose chemo-radiotherapy for relapsed or refractory Hodgkin lymphoma and the significance of pre-transplant functional imaging

scientific article published on 18 January 2010

Histone Deacetylase Inhibitors Synergistically Enhance the Cytotoxic Effect of Hypomethylating Agents in Models of Diffuse Large B-Cell Lymphoma. ⬇️

scholarly article

Histone deacetylase inhibitors demonstrate significant preclinical activity as single agents, and in combination with bortezomib in Waldenström's macroglobulinemia

scientific article published on February 2011

Histone deacetylase inhibitors: from target to clinical trials

scientific article

IL-22-Independent Protection from Colitis in the Absence of Nkx2.3 Transcription Factor in Mice

scientific article published on 30 January 2019

Identification of An Active, Well-Tolerated Dose of Pralatrexate In Patients with Relapsed or Refractory Cutaneous T-Cell Lymphoma (CTCL): Final Results of a Multicenter Dose-Finding Study. ⬇️

scholarly article

Identification of an active, well-tolerated dose of pralatrexate in patients with relapsed or refractory cutaneous T-cell lymphoma

scientific article

Imidazole Ketone Erastin Induces Ferroptosis and Slows Tumor Growth in a Mouse Lymphoma Model

scientific article published on 21 February 2019

Importance of early splenectomy in patients with hepatosplenic T-cell lymphoma and severe thrombocytopenia

scientific article

Interim Results from the First-in-Human Clinical Trial of Adct-402 (Loncastuximab Tesirine), a Novel Pyrrolobenzodiazepine-Based Antibody Drug Conjugate, in Relapsed/Refractory Diffuse Large B-Cell Lymphoma ⬇️

scholarly article

Intravenous Thrombolysis for Stroke and Presumed Stroke in Human Immunodeficiency Virus-Infected Adults: A Retrospective, Multicenter US Study.

scientific article published in January 2018

Manipulating the epigenome in germinal center lymphomas: is it getting easier and ezier?

scientific article published on 23 May 2014

Mantle cell lymphoma in relapse: the role of emerging new drugs.

scientific article published on September 2010

Mantle cell lymphoma: identifying novel molecular targets in growth and survival pathways

scientific article published on January 2007

Mantle cell lymphoma: report of the 2009 Mantle Cell Lymphoma Consortium Workshop

scientific article

Marked clinical activity of the proteasome inhibitor bortezomib in patients with follicular and mantle-cell lymphoma

scientific article

Mechanisms of Acquired Drug Resistance to the HDAC6 Selective Inhibitor Ricolinostat Reveals Rational Drug-Drug Combination with Ibrutinib

scientific article published on 19 December 2016

Mechanisms of Acquired Drug Resistance to the Isoform Selective HDAC6 Inhibitor Ricolinostat Reveals Markedly Upregulated Elements of the BTK Pathway Revealing Rational Drug : Drug Combinations ⬇️

scholarly article

Mechanistic rationale and clinical evidence for the efficacy of proteasome inhibitors against indolent and mantle cell lymphomas

scientific article

Mini BEAM with Full-Dose of Melphalan (beaM) As a Conditioning Regimen for High Risk Patients with NHL Undergoing Autologous SCT ⬇️

scholarly article

Modest benefit of total parenteral nutrition and chemotherapy after venting gastrostomy tube placement

scientific article published on 08 February 2013

Monomorphic T-cell post-transplant lymphoproliferative disorders exhibit markedly inferior outcomes compared to monomorphic B-cell post-transplant lymphoproliferative disorders

scientific article published on 01 September 2010

Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma

scientific article

Murine models in mantle cell lymphoma

scientific article published on 30 May 2012

Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity ⬇️

scientific article published on November 18, 2010

New directions in treating peripheral T-cell lymphomas (PTCL): leveraging epigenetic modifiers alone and in combination

scientific article published on 27 February 2019

New drugs for the treatment of advanced-stage diffuse large cell lymphomas

scientific article published on October 2006

New drugs for the treatment of lymphoma

scientific article published on October 2008

New strategies in peripheral T-cell lymphoma: understanding tumor biology and developing novel therapies

scientific article

New strategies in the treatment of mantle cell lymphoma.

scientific article

New strategies to optimize outcomes in patients with T-cell lymphoma

scientific article published on 01 September 2010

New therapeutic targets and drugs in non-Hodgkin's lymphoma

scientific article published on July 2011

Nimble micromanagement of macromolecules

scientific article published on 01 May 2009

Noninvasive phosphorus magnetic resonance spectroscopic imaging predicts outcome to first-line chemotherapy in newly diagnosed patients with diffuse large B-cell lymphoma

scientific article published on September 2013

Novel Agents in the Treatment of Relapsed or Refractory Peripheral T-Cell Lymphoma

scientific article

Novel Causal Inference Method Estimates Treatment Effects of Contemporary Drugs in a Global Cohort of Patients with Relapsed and Refractory Mature T-Cell and NK-Cell Neoplasms

scientific article published in 2023

Novel Drugs and Clinical Trial-Based Treatments Prolong Survival of Peripheral T-Cell Lymphomas (PTCL) Patients: Single Institution Retrospective Analysis ⬇️

scholarly article

Novel PI3K Inhibitors Demonstrated Marked Cytotoxicity in T Cell Lymphoma Models, Caused Apoptosis and Were Synergistic with A Novel Anti-CD20 Monoclonal Antibody Ublituximab in B Cell Lymphoma Models ⬇️

scholarly article

Novel agents in development for peripheral T-cell lymphoma

scientific article published on April 2010

Novel approaches for the treatment of NHL: Proteasome inhibition and immune modulation

scientific article published on January 2008

Novel disease targets and management approaches for diffuse large B-cell lymphoma

scientific article published on August 2010

Novel small molecules in the treatment of lymphomas.

scientific article

Novel therapeutic agents for cutaneous T-Cell lymphoma

scientific article

Nurturing a diet rich in PTCL

scientific article published on 01 October 2019

Objective responses in relapsed T-cell lymphomas with single-agent brentuximab vedotin.

scientific article published on 20 March 2014

Oral 5-azacytidine and romidepsin exhibit marked activity in patients with PTCL: a multicenter phase 1 study

scientific article published on 01 October 2019

PCDH10 promoter hypermethylation is frequent in most histologic subtypes of mature lymphoid malignancies and occurs early in lymphomagenesis

scientific article

PD-1 Blockade after Epigenetic Therapy in Patients with Relapsed or Refractory Hodgkin Lymphoma: Higher-Than-Expected Rate of Complete Responses ⬇️

scholarly article

PD-1 Is Elevated on the Peripheral Blood T Cell Subsets of Patients with Relapsed/Refractory Hodgkin Lymphoma Compared to Normal Volunteers ⬇️

scholarly article

PILLAR-1: Preliminary Results of a Phase II Study of mTOR Inhibitor Everolimus In Patients with Mantle Cell Lymphoma (MCL) Who Are Refractory or Intolerant to Bortezomib ⬇️

scholarly article

Pathologic and Clinical Features Of CD30+ Post-Transplant Lymphoproliferative Disorders: A Large Retrospective Single Institutional Study ⬇️

scholarly article

Patients with chemotherapy-refractory mantle cell lymphoma experience high response rates and identical progression-free survivals compared with patients with relapsed disease following treatment with single agent bortezomib: results of a multicentr

scientific article

Pegylated interferon plus rituximab in advanced stage, indolent lymphoma: is there CD20 antigen upregulation?

scientific article published on 01 July 2006

Phase 1 Dose-Escalation Study of Multiple Dosing Schedules of the Investigational Drug MLN4924, a Nedd8-Activating Enzyme Inhibitor, In Patients with Relapsed and/or Refractory Multiple Myeloma or Lymphoma. ⬇️

scholarly article

Phase 1/2a Study of ABT-263 in Relapsed or Refractory Lymphoid Malignancies. ⬇️

scholarly article

Phase 2 study of weekly bortezomib in mantle cell and follicular lymphoma

scientific article

Phase I Study of the Novel Investigational NEDD8-Activating Enzyme Inhibitor Pevonedistat (MLN4924) in Patients with Relapsed/Refractory Multiple Myeloma or Lymphoma

scientific article

Phase I clinical trial of histone deacetylase inhibitor: suberoylanilide hydroxamic acid administered intravenously.

scientific article

Phase I clinical, pharmacokinetic, and pharmacodynamic study of KOS-862 (Epothilone D) in patients with advanced solid tumors and lymphoma

scientific article

Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer

scientific article published on 16 May 2005

Phase I study of the novel epothilone analog ixabepilone (BMS-247550) in patients with advanced solid tumors and lymphomas

scientific article

Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies

scientific article

Phase I trial of weekly and twice-weekly bortezomib with rituximab, cyclophosphamide, and prednisone in relapsed or refractory non-Hodgkin lymphoma

scientific article published on 23 February 2011

Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma

scientific article

Phase II study of bortezomib in combination with rituximab, cyclophosphamide and prednisone with or without doxorubicin followed by rituximab maintenance in patients with relapsed or refractory follicular lymphoma

scientific article published on 9 July 2014

Phase II-I-II study of two different doses and schedules of pralatrexate, a high-affinity substrate for the reduced folate carrier, in patients with relapsed or refractory lymphoma reveals marked activity in T-cell malignancies

scientific article published on 3 August 2009

Phosphorus Magnetic Resonance Spectroscopy Predicts Outcome to Chemotherapy In Patients with Diffuse Large B-Cell Lymphoma: A Prospective International Multicenter Analysis of a Pretreatment Metabolic Biomarker of Response ⬇️

scholarly article

Pillar-1: Multicenter Phase 2 Study of Everolimus for Patients with Mantle Cell Lymphoma Who Are Refractory or Intolerant to Bortezomib. ⬇️

scholarly article

Plasmablastic lymphoma of the stomach.

scientific article published on July 2012

Post-transplant lymphoproliferative disorder: a heterogeneous conundrum - response to Weisenburger DD & Gross TG.

scientific article

Pralatrexate Has Potent Activity Against Multiple Myeloma In Vitro and In Vivo, and Activity Correlates with Tumor RFC-1 and DHFR Expression ⬇️

scholarly article

Pralatrexate Induces Responses in Patients with Highly Refractory Peripheral T-Cell Lymphoma (PTCL). ⬇️

scholarly article

Pralatrexate Is Active in Cutaneous T-Cell Lymphoma (CTCL): Results of a Multicenter, Dose-Finding Trial. ⬇️

scholarly article

Pralatrexate Is Effective as Second-Line Treatment Following Cyclophosphamide/Doxorubicin/Vincristine/Prednisone (CHOP) Failure In Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma (PTCL) ⬇️

scholarly article

Pralatrexate and Gemcitabine in Patients with Relapsed or Refractory Lymphoproliferative Malignancies: Phase 1 Results. ⬇️

scholarly article

Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study

scientific article

Pralatrexate is an effective treatment for relapsed or refractory transformed mycosis fungoides: a subgroup efficacy analysis from the PROPEL study

scientific article

Pralatrexate is synergistic with the proteasome inhibitor bortezomib in in vitro and in vivo models of T-cell lymphoid malignancies

scientific article

Pralatrexate pharmacology and clinical development

scientific article published on 21 August 2013

Pralatrexate, a novel class of antifol with high affinity for the reduced folate carrier-type 1, produces marked complete and durable remissions in a diversity of chemotherapy refractory cases of T-cell lymphoma

scientific article published in November 2007

Pralatrexate-Resistant Cell Lines Show Intact Internalization Via RFC1 but Collateral Sensitivity to Nucleoside Analogs ⬇️

scholarly article

Pralatrexate-induced tumor cell apoptosis in the epidermis of a patient with HTLV-1 adult T-cell lymphoma/leukemia causing skin erosions

scientific article

Pralatrexate: a comprehensive update on pharmacology, clinical activity and strategies to optimize use.

scientific article

Pralatrexate: an emerging new agent with activity in T-cell lymphomas

scientific article published on November 2006

Pralatrexate: basic understanding and clinical development

scientific article published on July 2010

Pre-Clinical Analysis Of The Novel Antifolate Pralatrexate In Multiple Myeloma Reveals Functional Biomarkers Correlated With Response ⬇️

scholarly article

Preclinical pharmacologic evaluation of pralatrexate and romidepsin confirms potent synergy of the combination in a murine model of human T-cell lymphoma

scientific article

Prediction and Early Detection of Response by NMR Spectroscopy and Imaging

scientific article

Predictive and Diagnostic Capabilities of Noninvasive MR Technology in Non-Hodgkin Lymphoma Patients. ⬇️

scholarly article

Prolonged Treatment with Brentuximab Vedotin (SGN-35) in Patients with Relapsed or Refractory Hodgkin Lymphoma (HL) or Systemic Anaplastic Large Cell Lymphoma (sALCL), ⬇️

scholarly article

Prolonged progression free survival in a subset of responders to the combination of brentuximab vedotin and bendamustine in heavily treated patients with relapsed or refractory Hodgkin lymphoma: updated results from an international multi-center pha

scientific article published on 28 July 2020

Promising activity of the proteasome inhibitor bortezomib (VELCADE) in the treatment of indolent non-Hodgkin's lymphoma and mantle cell lymphoma: ASH poster session 517-II.

scientific article published in November 2004

Prophylactic Placement of Internal Iliac Balloons in Patients with Abnormal Placental Implantation: Maternal and Foetal Outcomes

scientific article published on 18 May 2018

Propolis and its Active Component, Caffeic Acid Phenethyl Ester (CAPE), Modulate Breast Cancer Therapeutic Targets via an Epigenetically Mediated Mechanism of Action

scientific article published on October 2013

Putting the clinical and biological heterogeneity of non-hodgkin lymphoma into context

scientific article published on 01 October 2014

R-CHOP-14 in patients with diffuse large B-cell lymphoma: feasibility and preliminary efficacy

scientific article published in April 2005

Randomized Phase III Study of Alisertib or Investigator's Choice (Selected Single Agent) in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma

scientific article published on 01 February 2019

Recursive partitioning analysis of prognostic factors in post-transplant lymphoproliferative disorders (PTLD): a 120 case single institution series

scientific article

Resolving confusion: the new realities of mantle cell lymphoma.

scientific article

Risk-adapted dose-dense immunochemotherapy determined by interim FDG-PET in Advanced-stage diffuse large B-Cell lymphoma

scientific article published on 8 March 2010

Rituximab and ICE as second-line therapy before autologous stem cell transplantation for relapsed or primary refractory diffuse large B-cell lymphoma

scientific article

Role of stem cell transplant in CD30+ PTCL following frontline brentuximab vedotin plus CHP or CHOP in ECHELON-2

Romidepsin and belinostat synergize the antineoplastic effect of bortezomib in mantle cell lymphoma

scientific article

Safety and Management of Pralatrexate Treatment in Relapsed or Refractory Peripheral T-Cell Lymphoma (PTCL). ⬇️

scholarly article

Safety and efficacy of brentuximab vedotin for Hodgkin lymphoma recurring after allogeneic stem cell transplantation

scientific article

Safety and efficacy of pralatrexate in the treatment of patients with relapsed or refractory peripheral T-cell lymphoma

scientific article published on August 2012

Silencing c-Myc Translation As a Therapeutic Strategy through Targeting PI3K Delta and CK1 Epsilon in Hematological Malignancies ⬇️

scholarly article

Silencing c-Myc translation as a therapeutic strategy through targeting PI3Kδ and CK1ε in hematological malignancies

scientific article (publication date: 5 January 2017)

Sirtuin and pan-class I/II deacetylase (DAC) inhibition is synergistic in preclinical models and clinical studies of lymphoma

scientific article published on 2 August 2013

Stem Cell Transplant (SCT) and Pralatrexate Therapy: Outcome of Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma Who Received SCT Prior to or Following Pralatrexate Therapy. ⬇️

scholarly article

Strategy for Assessing New Drug Value in Orphan Diseases: An International Case Match Control Analysis of the PROPEL Study

scientific article published on 01 October 2018

Survival benefit in patients with peripheral T-cell lymphomas after treatments with novel therapies and clinical trials

scientific article published on 29 December 2019

Synergistic Combinations of Histone Deacetylase Inhibitors and Decitabine Induce a Unique Gene Expression and Epigenetic Profile In Models of Diffuse Large B-Cell Lymphoma ⬇️

scholarly article

T-Cell Lymphoma: Recent Advances in Characterization and New Opportunities for Treatment

scientific article published on 31 December 2016

TGR-1202, a Novel Once Daily PI3K-Delta Inhibitor, Demonstrates Clinical Activity with a Favorable Safety Profile in Patients with CLL and B-Cell Lymphoma ⬇️

scholarly article

Targeted treatment and new agents in peripheral T-cell lymphoma

scientific article published on 10 June 2010

Targeting Bcl-2 family members with the BH3 mimetic AT-101 markedly enhances the therapeutic effects of chemotherapeutic agents in in vitro and in vivo models of B-cell lymphoma

scientific article published on 21 February 2008

Targeting CD47 in Sézary syndrome with SIRPαFc

article

Targeting Epigenetic Operations with HDAC Inhibitor and Hypomethylating Drugs in Combination Exhibit Synergy in Preclinical and Clinical Experiences in Drug Resistant T-Cell Lymphoma (TCL): A Translational Focus on Doublet Development ⬇️

scholarly article

Targeting histone deacetyalses in the treatment of B- and T-cell malignancies

scientific article

Targeting histones and proteasomes: new strategies for the treatment of lymphoma

scientific article

Targeting survival pathways in lymphoma

scientific article published on January 1, 2010

The ATM Inhibitor KU60019 Synergizes the Antineoplastic Effect of Romidepsin in Mantle Cell Lymphoma (MCL) ⬇️

scholarly article

The Aurora A Kinase Inhibitor, Alisertib, Has Broad Activity In Nonclinical Models Of T-Cell Lymphoma and Is Highly Synergistic With Romidepsin, But Not With Pralatrexate Or The Proteasome Inhibitor, Ixazomib ⬇️

scholarly article

The BH3-only mimetic ABT-737 synergizes the antineoplastic activity of proteasome inhibitors in lymphoid malignancies

scientific article

The Combination of Histone Deacetylase Inhibitors and Hypomethylating Agents Exhibits Marked Synergy In Preclinical Models of T-Cell Lymphoma ⬇️

scholarly article

The ECHELON-2 Trial: Results of a Randomized, Double-Blind, Active-Controlled Phase 3 Study of Brentuximab Vedotin and CHP (A+CHP) Versus CHOP in the Frontline Treatment of Patients with CD30+ Peripheral T-Cell Lymphomas ⬇️

scholarly article

The First Case of Primary Cardiac Lymphoma, Diffuse Large B-Cell Type, Successfully Treated with EPOCH-R ⬇️

scholarly article

The HDACi Romidepsin Markedly Synergizes With Inhibition Of ATM By KU60019 In Mantle Cell Lymphoma ⬇️

scholarly article

The Investigational Aurora A Kinase Inhibitor Alisertib Exhibits Broad Activity in Preclinical Models of T-Cell Lymphoma and Is Highly Synergistic with Romidepsin ⬇️

scholarly article

The Novel Kinesin Spindle Protein Inhibitor SB-743921 Exhibits Marked Activity In In Vivo and In Vitro In Models of Aggressive Diffuse Large B-Cell Lymphoma ⬇️

scholarly article

The PI3K Delta Inhibitor TGR-1202 and Proteasome Inhibitor Carfilzomib Are Highly Synergistic In Killing Human B- and T-Cell Lymphoma Cells ⬇️

scholarly article

The Pralatrexate - Romidepsin Doublet: A Well Tolerated and Highly Effective Combination for Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma ⬇️

scholarly article

The addition of granulocyte-colony stimulating factor shifts the dose limiting toxicity and markedly increases the maximum tolerated dose and activity of the kinesin spindle protein inhibitor SB-743921 in patients with relapsed or refractory lymphom

scientific article

The anti-histaminic cyproheptadine synergizes the antineoplastic activity of bortezomib in mantle cell lymphoma through its effects as a histone deacetylase inhibitor.

scientific article published on 8 July 2009

The anti-tumor activity of pralatrexate (PDX) correlates with the expression of RFC and DHFR mRNA in preclinical models of multiple myeloma

scientific article published on 05 May 2020

The combination of hypomethylating agents and histone deacetylase inhibitors produce marked synergy in preclinical models of T-cell lymphoma

scientific article published on 20 July 2015

The combination of the proteasome inhibitor bortezomib and the bcl-2 antisense molecule oblimersen sensitizes human B-cell lymphomas to cyclophosphamide

scientific article published on May 2006

The emerging role of bortezomib in the treatment of indolent non-Hodgkin's and mantle cell lymphomas

scientific article published in August 2004

The novel IKK2 inhibitor LY2409881 potently synergizes with histone deacetylase inhibitors in preclinical models of lymphoma through the downregulation of NF-κB.

scientific article

The novel kinesin spindle protein (KSP) inhibitor SB-743921 exhibits marked activity in in vivo and in vitro models of aggressive large B-cell lymphoma

scientific article published on 10 April 2015

The peripheral T-cell lymphomas: an unusual path to cure

scientific article published on 01 October 2020

The rapidly changing landscape in mature T-cell lymphoma (MTCL) biology and management

scientific article published on 09 December 2019

The schedule-dependent effects of the novel antifolate pralatrexate and gemcitabine are superior to methotrexate and cytarabine in models of human non-Hodgkin's lymphoma

scientific article published in February 2006

Three-year outcomes with brentuximab vedotin plus bendamustine as first salvage therapy in relapsed or refractory Hodgkin lymphoma

scientific article published on 12 February 2020

Time to treatment response in patients with follicular lymphoma treated with bortezomib is longer compared with other histologic subtypes

scientific article

Tissue microarray analysis reveals protein expression patterns and potential biomarkers of clinical benefit to bortezomib in relapsed/refractory non-Hodgkin lymphoma

scientific article published on 26 April 2012

Translational Focus on Targeting HDAC6 with Ricolinostat Confirms Potent Activity in Preclinical Models of Lymphoma and a Favorable Toxicity Profile in Patients with Relapsed or Refractory Lymphoma ⬇️

scholarly article

Tumor-Specific T-Cells Engineered to Overcome Tumor Immune Evasion Induce Clinical Responses in Patients With Relapsed Hodgkin Lymphoma

scientific article published on 9 January 2018

Umbralisib, a novel PI3Kδ and casein kinase-1ε inhibitor, in relapsed or refractory chronic lymphocytic leukaemia and lymphoma: an open-label, phase 1, dose-escalation, first-in-human study

scientific article published on 20 February 2018

Update in T-cell lymphoma.

scientific article published on September 2010

Vitamin C antagonizes the cytotoxic effects of antineoplastic drugs

scientific article

Will new drugs change the standard of care for patients with mantle cell lymphoma?

scientific article

Paulina is supported by:

About Paulina

Help